Edition:
United States

Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

2.79USD
11 Dec 2017
Change (% chg)

$0.24 (+9.41%)
Prev Close
$2.55
Open
$2.61
Day's High
$2.80
Day's Low
$2.61
Volume
17,686
Avg. Vol
--
52-wk High
$6.35
52-wk Low
$2.40

Chart for

About

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent... (more)

Overall

Beta: 2.35
Market Cap(Mil.): $11.23
Shares Outstanding(Mil.): 4.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Aytu Bioscience files for mixed shelf of upto $100 mln

* Aytu Bioscience Inc files for mixed shelf of upto $100 million - SEC Filing Source text: [http://bit.ly/2B3AW23] Further company coverage:

Nov 22 2017

BRIEF-Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system

* Aytu Bioscience receives market approval from the Australian therapeutic goods administration for the Mioxsys® system for male infertility

Nov 07 2017

BRIEF-Aytu Bioscience CFO Gregory Gould resigns

* Aytu Bioscience Inc - ‍on October 26, 2017, Gregory A. Gould resigned as Chief Financial Officer​

Oct 27 2017

Earnings vs. Estimates